Discovery of a class of potent gap-junction modifiers as novel antiarrhythmic agents
摘要:
In an effort to discover potent, orally bioavailable compounds for the treatment of atrial fibrillation (AF) and ventricular tachycardia (VT), we developed a class of gap-junction modifiers typified by GAP-134 (1, R-1 = OH, R-2 = NH2), a compound currently under clinical evaluation. Selected compounds with the desired in-vitro profile demonstrated positive in vivo results in the mouse CaCl2 arrhythmia model upon oral administration. (C) 2009 Elsevier Ltd. All rights reserved.
Provided are methods for the preparation of certain substituted pyrrolidine compounds, forms of (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride, and methods for preparing and using these forms.
Provided are methods for the preparation of certain substituted pyrrolidine compounds, forms of (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride, and methods for preparing and using these forms.
[EN] SYNTHESIS OF PYRROLIDINE COMPOUNDS<br/>[FR] SYNTHÈSE DE COMPOSÉS DE PYRROLIDINE
申请人:WYETH CORP
公开号:WO2008079266A2
公开(公告)日:2008-07-03
[EN] Provided are methods for the preparation of certain substituted pyrrolidine compounds, forms of (2S, 4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride, and methods for preparing and using these forms. [FR] L'invention concerne des procédés de préparation de certains composés substitués de pyrrolidine, des formes de l'hydrochlorure d'acide (2S, 4R)-1-(2-aminoacétyl)-4-benzamidopyrrolidine-2-carboxylique. L'invention concerne également des procédés de préparation et d'utilisation de ces formes.